Merck: completes acquisition of Themis
(CercleFinance.com) - Merck announced on Friday that it has completed the acquisition of Themis, an Austrian company that is specialised in the development of vaccines for infectious diseases and immune-based therapies against cancer.
The US laboratory explains that the deal will in particular enable it to accelerate the development of a measles vaccine project that could be used against Covid-19.
This candidate vaccine, which is currently in pre-clinical development, could begin clinical trials by the end of the year.
Earlier this week, Merck completed the acquisition of Quantified Ag, a company that specialises in cattle temperature data and analysis to detect potential diseases at an early stage.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The US laboratory explains that the deal will in particular enable it to accelerate the development of a measles vaccine project that could be used against Covid-19.
This candidate vaccine, which is currently in pre-clinical development, could begin clinical trials by the end of the year.
Earlier this week, Merck completed the acquisition of Quantified Ag, a company that specialises in cattle temperature data and analysis to detect potential diseases at an early stage.
Copyright (c) 2020 CercleFinance.com. All rights reserved.